Deep search
All
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Search
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves new pain medicine
FDA approves opiate-alternative acute pain management drug, local experts share their thoughts
On Wednesday, the U.S. Food and Drug Administration approved a new pain management drug which could change the way healthcare providers address pain management.
FDA Approves the First Non-Opioid Pain Drug in 20 Years
The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and represent the first new class of pain medications in 20 years—and the first non-opioid painkiller since that class first appeared on the market in the 1980s.
FDA approves new pain medicine as opioid alternative. What to know about Journavx
The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.
1h
What to Know About Journavx, the Non-Opioid Pain Medication Just Approved by the FDA
The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...
Psychology Today
3h
Treating Pain—Avoiding the Brain
A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.
Healio
3h
FDA approves nonopioid Journavx for moderate to severe acute pain
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
C&EN
2h
FDA approves new nonopioid pain medication, hailed a 'triumph'
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
NOLA.com
1d
Get Back in the Game: Managing Knee Pain with ZILRETTA®
For active New Orleanians, knee osteoarthritis (OA) pain can sideline even the most passionate participants. Whether it’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback